 Bicycle Therapeutics plc NASDAQ: BCYC has announced interim Phase 1 results from the Phase 12 trial of BT8009, a second-generation BTC targeting Nectin-4, in patients with advanced solid tumors. The data will be presented at the 2022 American Association for Cancer Research. 